Dutasteride 0.5 Mg

take this medicine exactly as directed by your doctor. Do not take more of it, do not take it more often, and do not take it for a longer time than your doctor ordered. You may take this medicine with or without food. Swallow the capsule whole. Do not crush, chew, or open it. The contents of the capsule may irritate your lips, mouth,or throat.

Store the medicine in a closed container at room temperature, away from heat, moisture, and direct light.

Side effects may include impotence, decreased libido, ejaculation disorders, and breast enlargement and/or tenderness.

Evidence has demonstrated fetal abnormalities or risks when used during pregnancy.

Note: Women of childbearing potential should not use or handle dutasteride capsules. Dutasteride can cause birth defects in male fetuses. In Liver disease—Use with caution. The effects may be increased because of slower removal of the medicine from the body. Women and children should not use this medicine. Pregnant women or women who may become pregnant should not handle or touch the capsules. Dutasteride can be absorbed through the skin and can cause birth defects in male fetuses. If a pregnant woman does come in contact with this medicine, the affected area should be washed right away with soap and water, especially if the capsule is broken. Men who have taken this medicine should not donate blood until 6 months have passed since the last dose. Dutasteride can remain in your blood for a long time and be passed on to a pregnant woman who receives a blood transfusion.

Product Information: AVODART(R) oral capsules, dutasteride oral capsules. GlaxoSmithKline (Per FDA), Research Triangle Park, NC, 2011. Product Information: Avodart™, dutasteride. GlaxoSmithKline, Research Triangle Park, NC, 2003. Tsai TF, Choi GS, Kim BJ, et al: Prospective randomized study of sexual function in men taking dutasteride for the treatment of androgenetic alopecia. J Dermatol 2018; 45(7):799-804. PubMed Abstract: http://www.ncbi.nlm.nih.gov/..."

Systemic: Dutasteride inhibits the conversion of testosterone to 5α-dihydrotestosterone (DHT). DHT is the androgen primarily responsible for the initial development and subsequent enlargement of the prostate gland. Testosterone is converted to DHT by the enzyme 5α-reductase, which exists as 2 isoforms, type 1 and type 2. Type 2 isoenzyme is primarily active in the reproductive tissue while type 1 isoenzyme is responsible for testosterone conversion in the skin and liver.

Benign Prostatic Hypertrophy Agent.